MIR135A1

Summary

MIR135A1 (microRNA 135a-1, HGNC:31520) is a microRNA gene on chromosome 3p21.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406925 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31520
Approved symbol	MIR135A1
Name	microRNA 135a-1
Location	3p21.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-135-1, hsa-mir-135a-1
Ensembl gene	ENSG00000207926
Ensembl biotype	miRNA
Entrez	406925
RNAcentral	URS00005675D3 — miRNA, 90 nt, 16 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385191

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385191 — 1 exons

Exon	Start	End
ENSE00001500197	52294219	52294308

Expression profiles

Bgee: expression breadth broad, 44 present calls, max score 68.54.

Top tissues by expression

44 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
esophagogastric junction muscularis propria	UBERON:0035841	68.54	gold quality
left adrenal gland	UBERON:0001234	67.96	gold quality
blood	UBERON:0000178	67.89	gold quality
heart	UBERON:0000948	67.78	gold quality
heart left ventricle	UBERON:0002084	67.70	gold quality
gastrocnemius	UBERON:0001388	67.00	gold quality
spleen	UBERON:0002106	66.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	65.24	gold quality
lower esophagus muscularis layer	UBERON:0035833	64.93	gold quality
body of pancreas	UBERON:0001150	64.59	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	63.66	gold quality
Brodmann (1909) area 9	UBERON:0013540	63.09	gold quality
small intestine	UBERON:0002108	62.59	gold quality
thoracic mammary gland	UBERON:0005200	62.22	gold quality
ascending aorta	UBERON:0001496	61.86	gold quality
tibial artery	UBERON:0007610	61.12	gold quality
ectocervix	UBERON:0012249	61.08	gold quality
minor salivary gland	UBERON:0001830	60.76	gold quality
skin of leg	UBERON:0001511	60.57	gold quality
hypothalamus	UBERON:0001898	59.97	gold quality
caudate nucleus	UBERON:0001873	59.94	gold quality
right hemisphere of cerebellum	UBERON:0014890	59.93	gold quality
stomach	UBERON:0000945	59.83	gold quality
body of stomach	UBERON:0001161	58.73	gold quality
esophagus mucosa	UBERON:0002469	58.56	gold quality
nucleus accumbens	UBERON:0001882	58.23	gold quality
adipose tissue	UBERON:0001013	57.94	gold quality
omental fat pad	UBERON:0010414	57.87	gold quality
skin of abdomen	UBERON:0001416	57.61	gold quality
left uterine tube	UBERON:0001303	57.47	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• the miR-135 family regulates APC in colorectal cancer (PMID:18632633)
• the critical role of miR-135a in the survival of classic Hodgkin lymphoma cells and in the prognosis of classic Hodgkin lymphoma patients (PMID:19666866)
• these results demonstrate that by repressing the mineralocorticoid receptor gene NR3C2, miR-124 and miR-135a could participate in the regulation of renin-angiotensin-aldosterone system and thereby might be involved in blood pressure regulation. (PMID:19944075)
• Overexpression of miR-135a favors invasive and metastatic behavior in hepatocellular carcinoma. (PMID:21888875)
• Data suggest an important role of miR-135a in glioma etiology and provide a potential candidate for malignant glioma therapy. (PMID:22139076)
• Data show that the expression of the metastasis suppressor 1 (MTSS1) gene was regulated by miR-135a overexpression and knockdown. (PMID:23017832)
• High miR-135 is associated with anaplastic large cell lymphoma. (PMID:23594704)
• MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. (PMID:24465504)
• miR-135a/SIAH1/beta-catenin signaling is important in the transformation and progression of cervical carcinoma. (PMID:24503442)
• The findings suggest that ubiquitous loss of miR-135a expression is a critical mechanism for the overexpression of HOXA10 in epithelial ovarian cancer cells, which is implicated in epithelial ovarian carcinogenesis. (PMID:24607788)
• These findings suggest an important role for miR-135a in renal fibrosis and inhibition of miR-135a might be an effective therapy for diabetic nephropathy. (PMID:24908566)
• The results demonstrate that miR-135a targets Bmi1 in pancreatic ductal adenocarcinoma and functions as a tumor suppressor. (PMID:25013381)
• The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human prostate cancer. (PMID:25065599)
• A signature comprising three miRNAs (miR1290, miR196b, and miR135a*) enabled the prediction of a chemotherapeutic response (rather than progression-free and overall survival) with high accuracy in patients with recurring lung adenocarcinoma (PMID:25142144)
• it is probably that miR135b promotes proliferation, invasion and migration of osteosarcoma cells by degrading myocardin. (PMID:25190111)
• Therefore, we suggest that miR-135a regulation of LPS-induced apoptosis in A549 cells may depend in part on the regulation of Bcl-2. (PMID:25230140)
• miRNA-135a-5p increases BCL-2 via AP-2alpha and consequently enhances cell resistance to apoptosis. (PMID:25322930)
• MIRN135 microRNA is associated with initiation and progression of colonic polyp. (PMID:25496852)
• Aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNA135 and miRNA203. (PMID:25634212)
• miR-135a promotes cell proliferation in bladder cancer by targeting PHLPP2 and FOXO1, and is performed as an onco- (PMID:25888950)
• miR-135a and miR-135b were upregulated in models of podocyte injury and in glomeruli isolated from patients with focal segmental glomerulosclerosis. (PMID:26134897)
• These findings demonstrate a critical function for the astrocytic CEBPD, and point to miR-135a antagonist as an attractive therapeutic target for the treatment of Alzheimer’s disease. (PMID:26208701)
• MiR-135a inhibits migration and invasion and regulates epithelial-mesenchymal transition-related marker genes by targeting KLF8 in lung cancer cells. (PMID:26235874)
• Our findings suggested that miR-135a represents a potential onco-miRNA and plays an important role in malignant melanoma progression (PMID:26261511)
• Serum miR-135a-5p expression in colorectal cancer patients was higher than that in patients with colorectal polyps and healthy controls, suggesting that serum miR-135a-5p may prove to be an important biomarker for auxiliary diagnosis of colorectal cancer. (PMID:27126269)
• TGF-beta1 down-regulated KLF4 by activating miR-135a-5p, promoting proliferation and metastasis in hepatocellular carcinoma (PMID:27302923)
• miR-135a may represent a new diagnostic and therapeutic biomarker for castration-resistant prostate cancer. (PMID:27323416)
• Low MIRN135A1 expression is associated with prostate cancer. (PMID:27524492)
• Serum miR-135a level was downregulated in NSCLC patients, and was associated with poor prognosis. (PMID:27525941)
• Higher levels of miR-135a in gastric cancer (GC) are associated with shorter survival times and reduced times to disease recurrence. The mechanism whereby miR-135a promotes GC pathogenesis appears to be the suppression of E2F1 expression. (PMID:27683111)
• Transient transfection of miR-135a and miR-133b reduced viability and induced apoptosis in renal carcinoma cells. (PMID:27710896)
• MiR-135a-5p-regulated ROCK2 may play a role in the protective effects of hydrogen sulfide against Parkinson’s disease. (PMID:27842305)
• High intratumoral expression of miR-135a was associated with high risk of recurrence (HR = 4.2, p = 0.024, time to recurrence 8.8 +/- 2.0 vs. 24.8 +/- 4.4 months in patients with low miR-135a expression). (PMID:28100188)
• Hepatitis C virus promotes a STAT3 transcriptional programme in the liver of patients by suppressing its regulator PTPRD via upregulation of miR-135a-5p. (PMID:28159835)
• NCX1 is negatively regulated by miR-135a, a microRNA that is down-regulated in the heart after complete atrioventricular block in mice. By controlling NCX1 expression, miR-135a modulates cardiomyocyte automaticity, Ca2+ extrusion, and arrhythmogenic Ca2+ loading/spontaneous Ca2+ release events. Therefore, miR-135a may contribute to proarrhythmic remodeling after CAVB. (PMID:28188930)
• High amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. (PMID:28231414)
• this study shows that miR-135a is a key metastasis related miRNA and significantly downregulated in gastric cancer. Overexpression of miR-135a markedly inhibits the growth, migration and angiogenesis of gastric cancer by impairing FAK pathway. (PMID:28415713)
• The findings indicated that miR-135a promotes cell apoptosis and inhibits cell proliferation, migration, invasion and tumor angiogenesis by targeting IGF-1 gene through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer. (PMID:28715819)
• downregulation of miR-135a as a potential mechanism underlying the high NHE9 expression observed in subset of glioblastomas (PMID:29268774)
• The role of miR-135a in regulating epithelial-mesenchymal transition and the Wnt/beta-catenin signaling pathway in bladder cancer cells. (PMID:29350680)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir135b	ENSDARG00000082598
mus_musculus	Mir135a-1	ENSMUSG00000065407

Paralogs (2): MIR135B (ENSG00000199059), MIR135A2 (ENSG00000207586)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.